Modulating astrocyte transition after stroke to promote brain rescue and functional recovery: Emerging targets include Rho Kinase

International Journal of Molecular Sciences

Volumn 17, Issue 3, 2016, Pages

  Abeysinghe, Hima Charika S ^a   Phillips, Ellie L ^b   Chin Cheng, Heung ^b   Beart, Philip M ^c   Roulston, Carli L ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

Astrogliosis; Connectivity; Glial scar; Neurovascular unit; Regeneration; Rho kinase inhibition

Indexed keywords

ANGIOGENIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ARACHIDONIC ACID; COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; EPHRIN RECEPTOR; EPIDERMAL GROWTH FACTOR; ERYTHROPOIETIN; FIBROBLAST GROWTH FACTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR; GUANINE NUCLEOTIDE EXCHANGE FACTOR; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; HEXOKINASE; MONOCARBOXYLATE TRANSPORTER 4; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; RHO KINASE; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TYROSINE KINASE RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; NEUROPROTECTIVE AGENT; PROTEIN KINASE INHIBITOR;

ANAEROBIC METABOLISM; ANGIOGENESIS; ASTROCYTE; ASTROCYTOSIS; BLOOD BRAIN BARRIER; BRAIN FUNCTION; BRAIN PROTECTION; CEREBROVASCULAR ACCIDENT; EDEMA; GLIOSIS; HOMEOSTASIS; HUMAN; NERVE CONDUCTION; NEUROTRANSMISSION; NONHUMAN; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION; VASCULAR REMODELING; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; CYTOLOGY; DRUG EFFECTS; METABOLISM; STROKE;

ANIMALS; ASTROCYTES; BRAIN; HUMANS; NEUROPROTECTIVE AGENTS; PROTEIN KINASE INHIBITORS; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION; STROKE;

EID: 84959197229     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17030288     Document Type: Review

References (128)

1. Donnan, G.A.; Davis, S.M. Breaking the 3 h barrier for treatment of acute ischaemic stroke. Lancet Neurol. 2008, 7, 981–982. [CrossRef]
2. Sutherland, B.A.; Minnerup, J.; Balami, J.S.; Arba, F.; Buchan, A.M.; Kleinschnitz, C. Neuroprotection for ischaemic stroke: Translation from the bench to the bedside. Int. J. Stroke 2012, 7, 407–418. [CrossRef][PubMed]
3. Dalkara, T.; Alarcon-Martinez, L. Cerebral microvascular pericytes and neurogliovascular signaling in health and disease. Brain Res. 2015, 1623, 3–17. [CrossRef][PubMed]
4. Astrup, J.; Siesjö, B.K.; Symon, L. Thresholds in cerebral ischemia—The ischemic penumbra. Stroke 1981, 12, 723–725. [CrossRef][PubMed]
5. Mergenthaler, P.; Dirnagl, U.; Meisel, A. Pathophysiology of stroke: Lessons from animal models. Metab. Brain Dis. 2004, 19, 151–167. [CrossRef][PubMed]
6. Heiss, W.D.; Sobesky, J.; Hesselmann, V. Identifying thresholds for penumbra and irreversible tissue damage. Stroke 2004, 35, 2671–2674. [CrossRef][PubMed]
7. Busch, E.; Gyngell, M.L.; Eis, M.; Hoehn-Berlage, M.; Hossmann, K.A. Potassium-induced cortical spreading depressions during focal cerebral ischemia in rats: Contribution to lesion growth assessed by diffusion-weighted NMR and biochemical imaging. J. Cereb. Blood Flow Metab. 1996, 16, 1090–1099. [CrossRef][PubMed]
8. Popa-Wagner, A.; Badan, I.; Walker, L.; Groppa, S.; Patrana, N.; Kessler, C. Accelerated infarct development, cytogenesis and apoptosis following transient cerebral ischemia in aged rats. Acta Neuropathol. 2007, 113, 277–293. [CrossRef][PubMed]
9. Lo, E.H.; Rosenberg, G.A. The neurovascular unit in health and disease introduction. Stroke 2009, 40 (1), S2–S3. [CrossRef][PubMed]
10. Moskowitz, M.A.; Grotta, J.C.; Koroshetz, W.J. The NINDS Stroke Progress Review Group Final Analysis and Recommendations. Stroke 2013, 44, 2343–2550. [CrossRef][PubMed]
11. Del Zoppo, G.J. Inflammation and the neurovascular unit in the setting of focal cerebral ischemia. Neuroscience 2009, 158, 972–982. [CrossRef][PubMed]
12. Dirnagl, U. Pathobiology of injury after stroke: The neurovascular unit and beyond. Ann. N. Y. Acad. Sci. 2012, 1268, 21–25. [CrossRef][PubMed]
13. Moskowitz, M.A.; Lo, E.H.; Iadecola, C. The science of stroke: Mechanisms in search of treatments. Neuron 2010, 67, 181–198. [CrossRef][PubMed]
14. Kandel, E.R.; Schwartz, J.H.; Jessell, T.M. Principles of Neural Science, 4th ed.; McGraw-Hill: New York, NY, USA, 2000.
15. Del Zoppo, G. The neurovascular unit in the setting of stroke. J. Int. Med. 2010, 267, 156–171. [CrossRef][PubMed]
16. Reese, T.S.; Karnovsky, M.J. Fine structural localization of a blood-brain barrier to exogenous peroxidase. J. Cell Biol. 1967, 34, 207–217. [CrossRef][PubMed]
17. Engelhardt, B.; Sorokin, L. The blood-brain and the blood-cerebrospinal fluid barriers: Function and dysfunction. Semin. Immunopathol. 2009, 31, 497–511. [CrossRef][PubMed]
18. Armulik, A.; Genové, G.; Mäe, M.; Nisancioglu, M.H.; Wallgard, E.; Niaudet, C.; He, L.; Norlin, J.; Lindblom, P.; Strittmatter, K. et al. Pericytes regulate the blood-brain barrier. Nature 2010, 468, 557–561. [CrossRef][PubMed]
19. Abbott, N.J.; Rönnbäck, L.; Hansson, E. Astrocyte–endothelial interactions at the blood–brain barrier. Nat. Rev. Neurosci. 2006, 7, 41–53. [CrossRef][PubMed]
20. Rowland, L.P.; Fink, M.E.; Rubin, L. Cerebrospinal fluid: Blood brain barrier oedema and hydrocephalus. In Principles of Neural Science; Kandel, E.R., Schwartz, J.H., Jessell, T.M., Eds.; Elsevier: New York, NY, USA, 1992; pp. 1050–1060.
21. Okada, Y.; Copeland, B.R.; Mori, E.; Tung, M.M.; Thomas, W.S.; del Zoppo, G.J. P-selectin and intercellular adhesion molecule-1 expression after focal brain ischemia and reperfusion. Stroke 1994, 25, 202–211. [CrossRef][PubMed]
22. Strbian, D.; Durukan, A.; Pitkonen, M.; Marinkovic, I.; Tatlisumak, E.; Pedrono, E.; Abo-Ramadan, U.; Tatlisumak, T. The blood–brain barrier is continuously open for several weeks following transient focal cerebral ischemia. Neuroscience 2008, 153, 175–181. [CrossRef][PubMed]
23. Petty, M.A.; Wettstein, J.G. Elements of cerebral microvascular ischaemia. Brain Res. Rev. 2001, 36, 23–34. [CrossRef]
24. Durukan, A.; Tatlisumak, T. Acute ischemic stroke: Overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia. Pharmacol. Biochem. Behav. 2007, 87, 179–197. [CrossRef][PubMed]
25. Fagan, S.C.; Hess, D.C.; Hohnadel, E.J.; Pollock, D.M.; Ergul, A. Targets for vascular protection after acute ischemic stroke. Stroke 2004, 35, 2220–2225. [CrossRef][PubMed]
26. Ishrat, T.; Soliman, S.; Guan, W.; Saler, M.; Fagan, S.C. Vascular protection to increase the safety of tissue plasminogen activator for stroke. Curr. Pharm. Des. 2012, 18, 3677–3684. [CrossRef][PubMed]
27. Risau, W. Mechanisms of angiogenesis. Nature 1997, 386, 671–674. [PubMed]
28. Patan, S. Vasculogenesis and angiogenesis as mechanisms of vascular network formation, growth and remodeling. J. Neuro Oncol. 2000, 50, 1–15. [CrossRef]
29. Djonov, V.; Schmid, M.; Tschanz, S.A.; Burri, P.H. Intussusceptive angiogenesis its role in embryonic vascular network formation. Circ. Res. 2000, 86, 286–292. [CrossRef][PubMed]
30. Folkman, J.; Klagsbrun, M. Angiogenic factors. Science 1987, 235, 442–447. [CrossRef][PubMed]
31. Klagsbrun, M.; D’Amore, P.A. Regulators of angiogenesis. Annu. Rev. Physiol. 1991, 53, 217–239. [CrossRef][PubMed]
32. Plate, K.H. Mechanisms of angiogenesis in the brain. J. Neuropathol. Exp. Neurol. 1999, 58, 313–320. [CrossRef][PubMed]
33. Yancopoulos, G.D.; Klagsbrun, M.; Folkman, J. Vasculogenesis, angiogenesis, and growth factors: Ephrins enter the fray at the border. Cell 1998, 93, 661–664. [CrossRef]
34. Ergul, A.; Alhusban, A.; Fagan, S.C. Angiogenesis: A harmonized target for recovery after stroke. Stroke 2012, 43, 2270–2274. [CrossRef][PubMed]
35. Xiong, Y.; Mahmood, A.; Chopp, M. Angiogenesis, neurogenesis and brain recovery of function following injury. Curr. Opin. Investig. Drugs 2010, 11, 298–308. [PubMed]
36. Krupinski, J.; Kaluza, J.; Kumar, P.; Kumar, S.; Wang, J.M. Role of angiogenesis in patients with cerebral ischemic stroke. Stroke 1994, 25, 1794–1798. [CrossRef][PubMed]
37. Sbarbati, A.; Pietra, C.; Baldassarri, A.M.; Guerrini, U.; Ziviani, L.; Reggiani, A.; Boicelli, A.; Osculati, F. The microvascular system in ischemic cortical lesions. Acta Neuropathol. 1996, 92, 56–63. [CrossRef][PubMed]
38. Taylor, C.; Weston, R.M.; Dusting, G.J.; Roulston, C.L. NADPH Oxidase and Angiogenesis Following Endothelin-1 Induced Stroke in Rats: Role for Nox2 in Brain Repair. Brain Sci. 2013, 3, 294–317. [CrossRef][PubMed]
39. Zhang, Z.G.; Zhang, L.; Jiang, Q.; Zhang, R.; Davies, K.; Powers, C.; Bruggen, N.V.; Chopp, M. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J. Clin. Investig. 2000, 106, 829–838. [CrossRef][PubMed]
40. Hayashi, T.; Noshita, N.; Sugawara, T.; Chan, P.H. Temporal profile of angiogenesis and expression of related genes in the brain after ischemia. J. Cereb. Blood Flow Metab. 2003, 23, 166–180. [CrossRef][PubMed]
41. Zhang, Z.; Chopp, M. Vascular endothelial growth factor and angiopoietins in focal cerebral ischemia. Trends Cardiovasc. Med. 2002, 12, 62–66. [CrossRef]
42. Slevin, M.; Krupinski, J.; Slowik, A.; Kumar, P.; Szczudlik, A.; Gaffney, J. Serial measurement of vascular endothelial growth factor and transforming growth factor-_1 in serum of patients with acute ischemic stroke. Stroke 2000, 31, 1863–1870. [CrossRef][PubMed]
43. Krupinski, J.; Kaluza, J.; Kumar, P.; Wang, M.; Kumar, S. Prognostic value of blood vessel density in ischaemic stroke. Lancet 1993, 342, 742. [CrossRef]
44. Abeysinghe, H.C.S.; Bokhari, L.; Dusting, G.J.; Roulston, C.L. Brain Remodelling following Endothelin-1 Induced Stroke in Conscious Rats. PLoS ONE 2014, 9, e97007. [CrossRef][PubMed]
45. Buga, A.M.; Popa-Wagner, A. Neurovascular remodeling in the aged ischemic brain. J. Neural Transm. 2015, 122 (1), S25–S33.
46. Wang, L.; Zhang, Z.; Wang, Y.; Zhang, R.; Chopp, M. Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 2004, 35, 1732–1737. [CrossRef][PubMed]
47. Wang, L.; Chopp, M.; Gregg, S.R.; Zhang, R.L.; Teng, H.; Jiang, A.; Feng, Y.; Zhang, Z.G. Neural progenitor cells treated with EPO induce angiogenesis through the production of VEGF. J. Cereb. Blood Flow Metab. 2008, 28, 1361–1368. [CrossRef][PubMed]
48. Zacharek, A.; Chen, J.; Cui, X.; Li, A.; Li, Y.; Roberts, C.; Feng, Y.; Gao, Q.; Chopp, M. Angiopoietin1/Tie2 and VEGF/Flk1 induced by MSC treatment amplifies angiogenesis and vascular stabilization after stroke. J. Cereb. Blood Flow Metab. 2007, 27, 1684–1691. [CrossRef][PubMed]
49. Navaratna, D.; Guo, S.; Arai, K.; Lo, E.H. Mechanisms and targets for angiogenic therapy after stroke. Cell Adhes. Migr. 2009, 3, 216–223. [CrossRef]
50. Ridet, J.L.; Malhotra, S.K.; Privat, A.; Gage, F.H. Reactive astrocytes: Cellular and molecular cues to biological function. Trends Neurosci. 1997, 20, 570–577. [CrossRef]
51. Maragakis, N.J.; Rothstein, J.D. Mechanisms of disease: Astrocytes in neurodegenerative disease. Nat. Clin. Pract. Neurol. 2006, 2, 679–689. [CrossRef][PubMed]
52. Sofroniew, M.V.; Vinters, H.V. Astrocytes: Biology and pathology. Acta Neuropathol. 2010, 119, 7–35. [CrossRef][PubMed]
53. Zhang, R.; Wang, L.; Zhang, L.; Chen, J.; Zhu, Z.; Zhang, Z.; Chopp, M. Nitric oxide enhances angiogenesis via the synthesis of vascular endothelial growth factor and cGMP after stroke in the rat. Circ. Res. 2003, 92, 308–313. [CrossRef][PubMed]
54. Swanson, R.A.; Ying, W.; Kauppinen, T.M. Astrocyte influences on ischemic neuronal death. Curr. Mol. Med. 2004, 4, 193–205. [CrossRef][PubMed]
55. Potas, J.R.; Ying, W.; Kauppinen, T.M. Molecular and Cellular Changes in Stroke: An Emphasis on Glial and Inflammatory Mechanisms. In Focus on Stroke Research; Brown, S.P., Ed.; Nova Science Publishers, Inc.: New York, NY, USA, 2005; pp. 27–50.
56. Wilson, J.X. Antioxidant defense of the brain: A role for astrocytes. Can. J. Physiol. Pharmacol. 1997, 75, 1149–1163. [CrossRef][PubMed]
57. Bernaudin, M.; Bellail, A.; Marti, H.H.; Yvon, A.; Vivien, D.; Duchatelle, I.; Mackenzie, E.T.; Petit, E. Neurons and astrocytes express EPO mRNA: Oxygen-sensing mechanisms that involve the redox-state of the brain. Glia 2000, 30, 271–278. [CrossRef]
58. Buemi, M.; Cavallaro, E.; Floccari, F.; Sturiale, A.; Aloisi, C.; Trimarchi, M.; Corica, F.; Frisina, N. The pleiotropic effects of erythropoietin in the central nervous system. J. Neuropathol. Exp. Neurol. 2003, 62, 228–236. [CrossRef][PubMed]
59. Nagai, A.; Nakagawa, E.; Choi, H.B.; Hatori, K.; Kobayashi, S.; Kim, S.U. Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J. Neuropathol. Exp. Neurol. 2001, 60, 386–392. [CrossRef][PubMed]
60. Acker, T.; Beck, H.; Plate, K.H. Cell type specific expression of vascular endothelial growth factor and angiopoietin-1 and -2 suggests an important role of astrocytes in cerebellar vascularization. Mech. Dev. 2001, 108, 45–57. [CrossRef]
61. Mocchetti, I.; Wrathall, J.R. Neurotrophic factors in central nervous system trauma. J. Neurotrauma 1995, 12, 853–870. [CrossRef][PubMed]
62. Seifert, G.; Schilling, K.; Steinhäuser, C. Astrocyte dysfunction in neurological disorders: A molecular perspective. Nat. Rev. Neurosci. 2006, 7, 194–206. [CrossRef][PubMed]
63. Tokita, Y.; Keino, H.; Matsui, F.; Aono, S.; Ishiguro, H.; Higashiyama, S.; Oohira, A. Regulation of neuregulin expression in the injured rat brain and cultured astrocytes. J. Neurosci. 2001, 21, 1257–1264. [CrossRef]
64. Hirayama, Y.; Ikeda-Matsuo, Y.; Notomi, S.; Enaida, H.; Kinouchi, H.; Koizumi, S. Astrocyte-mediated ischemic tolerance. J. Neurosci. 2015, 35, 3794–3805. [CrossRef][PubMed]
65. Eng, L.F.; Ghirnikar, R.S.; Lee, Y.L. Glial fibrillary acidic protein: GFAP-thirty-one years (1969–2000). Neurochem. Res. 2000, 25, 1439–1451. [CrossRef][PubMed]
66. LeComte, M.D.; Shimada, I.S.; Sherwin, C.; Spees, J.L. Notch1-STAT3-ETBR signaling axis controls reactive astrocyte proliferation after brain injury. Proc. Natl. Acad. Sci. USA 2015, 112, 8726–8731. [CrossRef][PubMed]
67. Takano, T.; Kang, J.; Jaiswal, J.K.; Simon, S.M.; Lin, J.H.; Yu, Y.; Li, Y.; Yang, J.; Dienel, G.; Zielke, H.R. et al. Receptor-mediated glutamate release from volume sensitive channels in astrocytes. Proc. Natl. Acad. Sci. USA 2005, 102, 16466–16471. [CrossRef][PubMed]
68. Venero, J. L.; Vizuete, M.L.; Machado, A.; Cano, J. Aquaporins in the central nervous system. Prog. Neurobiol. 2001, 63, 321–336. [CrossRef]
69. Badan, I.; Buchhold, B.; Hamm, A.; Gratz, M.; Walker, L.C.; Platt, D.; Kessler, C.H.; Popa-Wagner, A. Accelerated glial reactivity to stroke in aged rats correlates with reduced functional recovery. J. Cereb. Blood Flow. Metab. 2003, 23, 845–854. [CrossRef][PubMed]
70. Hossain, M.I.; Roulston, C.L.; Stapleton, D.I. Molecular basis of impaired glycogen metabolism during ischemic stroke and hypoxia. PLoS ONE 2014, 9, e97570. [CrossRef][PubMed]
71. Le Clainche, C.; Carlier, M.F. Regulation of actin assembly associated with protrusion and adhesion in cell migration. Physiol. Rev. 2008, 88, 489–513. [CrossRef][PubMed]
72. Mattila, P.K.; Lappalainen, P. Filopodia: Molecular architecture and cellular functions. Nat. Rev. Mol. Cell Biol. 2008, 9, 446–454. [CrossRef][PubMed]
73. Lau, C.L.; O’Shea, R.D.; Broberg, B.V.; Bischof, L.; Beart, P.M. The Rho kinase inhibitor Fasudil up-regulates astrocytic glutamate transport subsequent to actin re-modelling in cultured murine astrocytes. Br. J. Pharmacol. 2011, 163, 533–545. [CrossRef][PubMed]
74. Lau, C.L.; Perreau, V.M.; Chen, M.J.; Cate, H.S.; Merlo, D.; Cheung, N.S.; O’Shea, R.D.; Beart, P.M. Transcriptomic profiling of astrocytes treated with the rho kinase inhibitor Fasudil reveals cytoskeletal and pro-survival responses. J. Cell. Physiol. 2012, 227, 1199–1211. [CrossRef][PubMed]
75. Sheean, R.K.; Lau, C.L.; Shin, Y.S.; O’Shea, R.D.; Beart, P.M. Links between L-glutamate transporters, Na+/K+-ATPase and cytoskeleton in astrocytes: Evidence following inhibition with rottlerin. Neuroscience 2013, 254, 335–346. [CrossRef][PubMed]
76. Lau, C.L.; Kovacevic, M.; Tingleff, T.S.; Forsythe, J.S.; Cate, H.S.; Merlo, D.; Cederfur, C.; Maclean, F.L.; Parish, C.L.; Horne, M.K. et al. 3D Electrospun scaffolds promote a cytotrophic phenotype of cultured primary astrocytes. J. Neurochem. 2014, 130, 215–226. [CrossRef][PubMed]
77. O’Shea, R.D.; Lau, C.L.; Zulaziz, N.B.; Maclean, F.L.; Nisbet, D.R.; Horne, M.K.; Beart, P.M. Transcriptomic analysis and 3D bioengineering of astrocytes indicate ROCK inhibition produces cytotrophic astrogliosis. Front. Neurosci. 2015, 9, 50. [CrossRef][PubMed]
78. Cahoy, J.D.; Emery, B.; Kaushal, A.; Foo, L.C.; Zamanian, J.L.; Christopherson, K.S.; Xing, Y.; Lubischer, J.L.; Krieg, P.A.; Krupenko, S.A. et al. A transcriptome database for astrocytes, neurons, and oligodendrocytes: A new resource for understanding brain development and function. J. Neurosci. 2008, 28, 264–278. [CrossRef][PubMed]
79. Shen, C.C.; Yang, Y.C.; Chiao, M.T.; Cheng, W.Y.; Tsuei, Y.S.; Ko, J.L. Characterization of endogenous neural progenitor cells after experimental ischemic stroke. Curr. Neurovasc. Res. 2010, 7, 6–14. [CrossRef][PubMed]
80. Carrera, E.; Tononi, G. Diaschisis: Past, present, future. Brain 2014, 137, 2408–2422. [CrossRef][PubMed]
81. Silver, J.; Miller, J.H. Regeneration beyond the glial scar. Nat. Rev. Neurosci. 2004, 5, 146–156. [CrossRef][PubMed]
82. Fitch, M.T.; Silver, J. CNS injury, glial scars, and inflammation: Inhibitory extracellular matrices and regeneration failure. Exp. Neurol. 2008, 209, 294–301. [CrossRef][PubMed]
83. Fawcett, J.W.; Asher, R.A. The glial scar and central nervous system repair. Brain Res. Bull. 1999, 49, 377–391. [CrossRef]
84. Canning, D.R.; Höke, A.; Malemud, C.J.; Silver, J. A potent inhibitor of neurite outgrowth that predominates in the extracellular matrix of reactive astrocytes. Int. J. Dev. Neurosci. 1996, 14, 153–175. [CrossRef]
85. McKeon, R.J.; Jurynec, M.J.; Buck, C.R. The chondroitin sulfate proteoglycans neurocan and phosphacan are expressed by reactive astrocytes in the chronic CNS glial scar. J. Neurosci. 1999, 19, 10778–10788. [PubMed]
86. Busch, S.A.; Silver, J. The role of extracellular matrix in CNS regeneration. Curr. Opin. Neurobiol. 2007, 17, 120–127. [CrossRef][PubMed]
87. Sandvig, A.; Berry, M.; Barrett, L.B.; Butt, A.; Logan, A. Myelin-, reactive glia-, and scar-derived CNS axon growth inhibitors: Expression, receptor signaling, and correlation with axon regeneration. Glia 2004, 46, 225–251. [CrossRef][PubMed]
88. Schwab, M.E. Nogo and axon regeneration. Curr. Opin. Neurobiol. 2004, 14, 118–124. [CrossRef][PubMed]
89. He, Z.; Koprivica, V. The Nogo Signaling Pathway for Regeneration Block. Annu. Rev. Neurosci. 2004, 27, 341–368. [CrossRef][PubMed]
90. Schwab, J.M.; Conrad, S.; Monnier, P.P.; Julien, S.; Mueller, B.K.; Schluesener, H.J. Spinal cord injury-induced lesional expression of the repulsive guidance molecule (RGM). Eur. J. Neurosci. 2005, 21, 1569–1576. [CrossRef][PubMed]
91. Li, L.; Lundkvist, A.; Andersson, D.; Wilhelmsson, U.; Nagai, N.; Pardo, A.C.; Nodin, C.; Ståhlberg, A.; Aprico, K.; Larsson, K. et al. Protective role of reactive astrocytes in brain ischemia. J. Cereb. Blood Flow Metab. 2008, 28, 468–481. [CrossRef][PubMed]
92. Liu, Z.; Li, Y.; Cui, Y.; Roberts, C.; Lu, M.; Wilhelmsson, U.; Pekny, M.; Chopp, M. Beneficial effects of gfap/vimentin reactive astrocytes for axonal remodeling and motor behavioral recovery in mice after stroke. Glia 2014, 62, 2022–2033. [CrossRef][PubMed]
93. Herrmann, J.E.; Imura, T.; Song, B.; Qi, J.; Ao, Y.; Nguyen, T.K.; Korsak, R.A.; Takeda, K.; Akira, S.; Sofroniew, M.V. STAT3 is a critical regulator of astrogliosis and scar formation after spinal cord injury. J. Neurosci. 2008, 28, 7231–7243. [CrossRef][PubMed]
94. Okada, S.; Nakamura, M.; Katoh, H.; Miyao, T.; Shimazaki, T.; Ishii, K.; Yamane, J.; Yoshimura, A.; Iwamoto, Y.; Toyama, Y. et al. Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after spinal cord injury. Nat. Med. 2006, 12, 829–834. [CrossRef][PubMed]
95. Roitbak, T.; Sykova, E. Diffusion barriers evoked in the rat cortex by reactive astrogliosis. Glia 1999, 28, 40–48. [CrossRef]
96. Buchhold, B.; Mogoanta, L.; Suofu, Y.; Hamm, A.; Walker, L.; Kessler, C.H.; Popa-Wagner, A. Environmental enrichment improves functional and neuropathological indices following stroke in young and aged rats. Restor. Neurol. Neurosci. 2007, 25, 467–484. [PubMed]
97. Abeysinghe, H.C.S.; Bokhari, L.; Dusting, G.J.; Roulston, C.L. Cyclosporine A reduces glial scarring and facilitates functional recovery following transient focal ischemia. J. Neurol. Neurophysiol. 2015, 6, 227. [CrossRef]
98. Sofroniew, M.V. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci. 2009, 32, 638–647. [CrossRef][PubMed]
99. Riento, K.; Ridley, A.J. Rocks: Multifunctional kinases in cell behaviour. Nat. Rev. Mol. Cell Biol. 2003, 4, 446–456. [CrossRef][PubMed]
100. Amano, M.; Nakayama, M.; Kaibuchi, K. Rho-kinase/ROCK: A key regulator of the cytoskeleton and cell polarity. Cytoskeleton 2010, 67, 545–554. [CrossRef][PubMed]
101. Matsui, T.; Maeda, M.; Doi, Y.; Yonemura, S.; Amano, M.; Kaibuchi, K.; Tsukita, S.; Tsukita, S. Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association. J. Cell Biol. 1998, 140, 647–657. [CrossRef][PubMed]
102. Shi, J.; Wei, L. Rho kinase in the regulation of cell death and survival. Arch. Immunol. Ther. Exp. 2007, 55, 61–75. [CrossRef][PubMed]
103. Brabeck, C.; Mittelbronn, M.; Bekure, K.; Meyermann, R.; Schluesener, H.J.; Schwab, J.M. Effect of focal cerebral infarctions on lesional RhoA and RhoB expression. Arch. Neurol. 2003, 60, 1245–1249. [CrossRef][PubMed]
104. Yano, K.; Kawasaki, K.; Hattori, T.; Tawara, S.; Toshima, Y.; Ikegaki, I.; Sasaki, Y.; Satoh, S.I.; Asano, T.; Seto, M.Demonstration of elevation and localization of Rho-kinase activity in the brain of a rat model of cerebral infarction. Eur. J. Pharmacol. 2008, 594, 77–83. [CrossRef][PubMed]
105. Abe, K.; Misawa, M. Astrocyte stellation induced by Rho kinase inhibitors in culture. Dev. Brain Res. 2003, 143, 99–104. [CrossRef]
106. Murk, K.; Blanco Suarez, E.M.; Cockbill, L.M.; Banks, P.; Hanley, J.G. The antagonistic modulation of Arp2/3 activity by N-WASP, WAVE2 and PICK1 defines dynamic changes in astrocyte morphology. J. Cell Sci. 2013, 126, 3873–3883. [CrossRef][PubMed]
107. Borisoff, J.F.; Chan, C.C.M.; Hiebert, G.W.; Oschipok, L.; Robertson, G.S.; Zamboni, R.; Steeves, J.D.; Tetzlaff, W. Suppression of Rho-kinase activity promotes axonal growth on inhibitory CNS substrates. Mol. Cell. Neurosci. 2003, 22, 405–416. [CrossRef]
108. Fournier, A.E.; Takizawa, B.T.; Strittmatter, S.M. Rho Kinase Inhibition Enhances Axonal Regeneration in the Injured CNS. J. Neurosci. 2003, 23, 1416–1423. [PubMed]
109. Schnell, L.; Schwab, M.E. Axonal regeneration in the rat spinal cord produced by an antibody against myelin-associated neurite growth inhibitors. Nature 1990, 343, 269–272. [CrossRef][PubMed]
110. Gopalakrishnan, S.M.; Teusch, N.; Imhof, C.; Bakker, M.H.M.; Schurdak, M.; Burns, D.J.; Warrior, U. Role of Rho kinase pathway in chondroitin sulfate proteoglycan-mediated inhibition of neurite outgrowth in PC12 cells. J. Neurosci. Res. 2008, 86, 2214–2226. [CrossRef][PubMed]
111. Monnier, P.P.; Sierra, A.; Schwab, J.M.; Henke-Fahle, S.; Mueller, B.K. The Rho/ROCK pathway mediates neurite growth-inhibitory activity associated with the chondroitin sulfate proteoglycans of the CNS glial scar. Mol. Cell. Neurosci. 2003, 22, 319–330. [CrossRef]
112. Lingor, P.; Teusch, N.; Schwarz, K.; Mueller, R.; Mack, H.; Bähr, M.; Mueller, B.K. Inhibition of Rho kinase (ROCK) increases neurite outgrowth on chondroitin sulphate proteoglycan in vitro and axonal regeneration in the adult optic nerve in vivo. J. Neurochem. 2007, 103, 181–189. [CrossRef][PubMed]
113. Jacobs, M.; Hayakawa, K.; Swenson, L.; Bellon, S.; Fleming, M.; Taslimi, P.; Doran, J. The Structure of Dimeric ROCK I Reveals the Mechanism for Ligand Selectivity. J. Biol. Chem. 2005, 281, 260–268. [CrossRef][PubMed]
114. Satoh, S.; Utsunomiya, T.; Tsurui, K.; Kobayashi, T.; Ikegaki, I.; Sasaki, Y.; Asano, T. Pharmacological profile of hydroxy Fasudil as a selective rho kinase inhibitor on ischemic brain damage. Life Sci. 2001, 69, 1441–1453. [CrossRef]
115. Zhao, J.; Zhou, D.; Guo, J.; Ren, Z.; Zhou, L.; Wang, S.; Zhang, Y.; Xu, B.; Zhao, K.; Wang, R. et al. Efficacy and safety of Fasudil in patients with subarachnoid hemorrhage: Final results of a randomized trial of Fasudil versus nimodipine. Neurol. Med. Chir. 2011, 51, 679–683. [CrossRef]
116. Takata, M.; Tanaka, H.; Kimura, M.; Nagahara, Y.; Tanaka, K.; Kawasaki, K.; Seto, M.; Tsuruma, K.; Shimazawa, M.; Hara, H. Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis. Br. J. Pharmacol. 2013, 170, 341–351. [CrossRef][PubMed]
117. Yu, J.Z.; Ding, J.; Ma, C.G.; Sun, C.H.; Sun, Y.F.; Lu, C.Z.; Xiao, B.G. Therapeutic potential of experimental autoimmune encephalomyelitis by Fasudil, a Rho kinase inhibitor. J. Neurosci. Res. 2010, 88, 1664–1672. [CrossRef][PubMed]
118. Hara, M.; Takasu, M.; Watanabe, K.; Noda, A.; Takagi, T.; Suzuki, Y.; Yoshida, J. Protein kinase inhibition by fasudil hydrochloride promotes neurological recovery after spinal cord injury in rats. J. Neurosurg. 2000, 93, 94–101. [CrossRef][PubMed]
119. Shibuya, M.; Hirai, S.; Seto, M.; Satoh, S.I.; Ohtomo, E. Effects of fasudil in acute ischemic stroke: Results of a prospective placebo-controlled double-blind trial. J. Neurol. Sci. 2005, 238, 31–39. [CrossRef][PubMed]
120. Rikitake, Y.; Kim, H.H.; Huang, Z.; Seto, M.; Yano, K.; Asano, T.; Moskowitz, M.A.; Liao, J.K. Inhibition of Rho Kinase (ROCK) Leads to Increased Cerebral Blood Flow and Stroke Protection. Stroke 2005, 36, 2251–2257. [CrossRef][PubMed]
121. Wu, J.; Li, J.; Hu, H.; Liu, P.; Fang, Y.; Wu, D. Rho-Kinase Inhibitor, Fasudil, Prevents Neuronal Apoptosis via the Akt Activation and PTEN Inactivation in the Ischemic Penumbra of Rat Brain. Cell. Mol. Neurobiol. 2012, 32, 1187–1197. [CrossRef][PubMed]
122. Ding, J.; Yu, J.Z.; Li, Q.Y.; Wang, X.; Lu, C.Z.; Xiao, B.G. Rho kinase inhibitor Fasudil induces neuroprotection and neurogenesis partially through astrocyte-derived G-CSF. Brain Behav. Immun. 2009, 23, 1083–1088. [CrossRef][PubMed]
123. Yamashita, K.; Kotani, Y.; Nakajima, Y.; Shimazawa, M.; Yoshimura, S.I.; Nakashima, S.; Iwama, T.; Hara, H. Fasudil, a Rho kinase (ROCK) inhibitor, protects against ischemic neuronal damage in vitro and in vivo by acting directly on neurons. Brain Res. 2007, 1154, 215–224. [CrossRef][PubMed]
124. Gibson, C.L.; Srivastava, K.; Sprigg, N.; Bath, P.M.; Bayraktutan, U. Inhibition of Rho-kinase protects cerebral barrier from ischaemia-evoked injury through modulations of endothelial cell oxidative stress and tight junctions. J. Neurochem. 2014, 129, 816–826. [CrossRef][PubMed]
125. Huang, L.; He, Z.; Guo, L.; Wang, H. Improvement of Cognitive Deficit and Neuronal Damage in Rats with Chronic Cerebral Ischemia via Relative Long-term Inhibition of Rho-kinase. Cell. Mol. Neurobiol. 2008, 28, 757–768. [CrossRef][PubMed]
126. Lemmens, R.; Jaspers, T.; Robberecht, W.; Thijs, V.N. Modifying expression of EphA4 and its downstream targets improves functional recovery after stroke. Hum. Mol. Genet. 2013, 22, 2214–2220. [CrossRef][PubMed]
127. Tura, A.; Schuettauf, F.; Monnier, P.P.; Bartz-Schmidt, K.U.; Henke-Fahle, S. Efficacy of Rho-kinase inhibition in promoting cell survival and reducing reactive gliosis in the rodent retina. Investig. Ophthalmol. Vis. Sci. 2009, 50, 452–461. [CrossRef][PubMed]
128. Phillips, E.J.; Bokhari, L.; Seng, C.; Heung, C.C.; Roulston, C.L. Inhibition of Rho-kinase to Reduce Astrocyte Reactivity And Promote Recovery After Stroke. Unpublished data, 2016.